Green Biologics has closed its B round at $25m following investment from Sofinnova and Swire, and will now focus on it commercialisation efforts.

Swire Pacific Limited, a UK-based diversified corporation, has participated in a $25m B round for UK-based Green Biologics, an industrial biotechnology company.  The round was led by venture capital firm Sofinnova Partners, with involvement from Capricorn Venture Partners, Oxford Capital Partners, Morningside Ventures and ConvergInce Holdings.

Chief executive of Green Biologics, Sean Sutcliffe, said: “As well as bringing exceptional skills and experience from our new investors to accelerate the development of the company, this investment round underlines the strength of Green Biologics’ commercial and…